Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Stockholders' Equity

v3.19.2
Condensed Statements of Stockholders' Equity - USD ($)
Class A Preferred Stock
Class A Common Shares
Common Shares
Common Stock Issuable
Additional Paid-in Capital
Accumulated Deficit
Total
Balances at Dec. 31, 2017 $ 0 $ 0 $ 3,000 $ 9,558,000 $ 98,679,000 $ (48,408,000) $ 59,832,000
Balances (in shares) at Dec. 31, 2017 250,000 1,000,000 25,236,255        
Issuance of common shares - Founders Agreement $ 0 $ 0 $ 0 (9,558,000) 9,558,000 0 0
Issuance of common shares - Founders Agreement (in shares) 0 0 834,756        
Stock-based compensation expenses $ 0 $ 0 $ 0 0 2,966,000 0 2,966,000
Stock-based compensation expenses (in shares) 0 0 150,000        
Exercise of warrants $ 0 $ 0 $ 0 0 181,000 0 181,000
Exercise of warrants (in shares) 0 0 42,343        
Net loss $ 0 $ 0 $ 0 0 0 (11,374,000) (11,374,000)
Balances at Jun. 30, 2018 $ 0 $ 0 $ 3,000 0 111,384,000 (59,782,000) 51,605,000
Balances (in shares) at Jun. 30, 2018 250,000 1,000,000 26,263,354        
Balances at Mar. 31, 2018 $ 0 $ 0 $ 3,000 0 110,328,000 (54,689,000) 55,642,000
Balances (in shares) at Mar. 31, 2018 250,000 1,000,000 26,101,554        
Stock-based compensation expenses $ 0 $ 0 $ 0 0 971,000 0 971,000
Stock-based compensation expenses (in shares) 0 0 150,000        
Exercise of warrants $ 0 $ 0 $ 0 0 85,000 0 85,000
Exercise of warrants (in shares) 0 0 11,800        
Net loss $ 0 $ 0 $ 0 0 0 (5,093,000) (5,093,000)
Balances at Jun. 30, 2018 $ 0 $ 0 $ 3,000 0 111,384,000 (59,782,000) 51,605,000
Balances (in shares) at Jun. 30, 2018 250,000 1,000,000 26,263,354        
Balances at Dec. 31, 2018 $ 0 $ 0 $ 3,000 2,085,000 113,378,000 (79,070,000) 36,396,000
Balances (in shares) at Dec. 31, 2018 250,000 1,000,000 26,610,183        
Issuance of common shares - Founders Agreement $ 0 $ 0 $ 0 (2,085,000) 2,085,000 0 0
Issuance of common shares - Founders Agreement (in shares) 0 0 709,314        
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech $ 0 $ 0 $ 0 0 375,000 0 375,000
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech (in shares) 0 0 108,069        
Issuance of warrants - Horizon Note $ 0 $ 0 $ 0 0 888,000 0 888,000
Issuance of warrants - Horizon Note (in shares) 0 0 0        
Conversion of Class A common shares to common shares $ 0 $ 0 $ 0 0 0 0 0
Conversion of Class A common shares to common shares (In Shares) 0 (137,608) 137,608        
Issuance of common shares, net of offering costs - At-the-Market Offering $ 0 $ 0 $ 0 0 21,972,000 0 21,972,000
Issuance of common shares, net of offering costs - At-the-Market Offering (in Shares) 0 0 3,506,222        
Issuance of common shares - Equity fee on At-the-Market Offering $ 0 $ 0 $ 0 0 495,000 0 495,000
Issuance of common shares - Equity fee on At-the-Market Offering ( in Shares) 0 0 87,656        
Issuance of common shares, net of offering costs - Public Offering $ 0 $ 0 $ 1,000 0 29,484,000 0 29,485,000
Issuance of common shares, net of offering costs - Public Offering (In shares) 0 0 7,906,250        
Issuance of common shares - Equity fee on Public Offering $ 0 $ 0 $ 0 0 791,000 0 791,000
Issuance of common shares - Equity fee on Public Offering (In Shares) 0 0 197,656        
Stock-based compensation expenses $ 0 $ 0 $ 0 0 1,054,000 0 1,054,000
Stock-based compensation expenses (in shares) 0 0 126,000        
Exercise of warrants $ 0 $ 0 $ 0 0   0 0
Exercise of warrants (in shares) 0 0 65,358        
Net loss $ 0 $ 0 $ 0 0 0 (20,012,000) (20,012,000)
Balances at Jun. 30, 2019 $ 0 $ 0 $ 4,000 0 170,522,000 (99,082,000) 71,444,000
Balances (in shares) at Jun. 30, 2019 250,000 862,392 39,454,316        
Balances at Mar. 31, 2019 $ 0 $ 0 $ 3,000 0 117,158,000 (88,683,000) 28,478,000
Balances (in shares) at Mar. 31, 2019 250,000 1,000,000 27,561,433        
Conversion of Class A common shares to common shares $ 0 $ 0 $ 0 0 0 0 0
Conversion of Class A common shares to common shares (In Shares) 0 (137,608) 137,608        
Issuance of common shares, net of offering costs - At-the-Market Offering $ 0 $ 0 $ 0 0 21,972,000 0 21,972,000
Issuance of common shares, net of offering costs - At-the-Market Offering (in Shares) 0 0 3,506,222        
Issuance of common shares - Equity fee on At-the-Market Offering $ 0 $ 0 $ 0 0 495,000 0 495,000
Issuance of common shares - Equity fee on At-the-Market Offering ( in Shares) 0 0 87,656        
Issuance of common shares, net of offering costs - Public Offering $ 0 $ 0 $ 1,000 0 29,484,000 0 29,485,000
Issuance of common shares, net of offering costs - Public Offering (In shares) 0 0 7,906,250        
Issuance of common shares - Equity fee on Public Offering $ 0 $ 0 $ 0 0 791,000 0 791,000
Issuance of common shares - Equity fee on Public Offering (In Shares) 0 0 197,656        
Stock-based compensation expenses $ 0 $ 0 $ 0 0 622,000 0 622,000
Stock-based compensation expenses (in shares) 0 0 50,000        
Exercise of warrants $ 0 $ 0 $ 0 0 0 0 0
Exercise of warrants (in shares) 0 0 7,491        
Net loss $ 0 $ 0 $ 0 0 0 (10,399,000) (10,399,000)
Balances at Jun. 30, 2019 $ 0 $ 0 $ 4,000 $ 0 $ 170,522,000 $ (99,082,000) $ 71,444,000
Balances (in shares) at Jun. 30, 2019 250,000 862,392 39,454,316